Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

CP 461

SKU: orb1697727

Description

CP 461 (UNII-68OJX9I7DT) is a selective PDE2A inhibitor that induces apoptosis in various human cancer cell lines in vitro while sparing normal cells. Its research applications include studying cyclic nucleotide signaling in oncology and exploring its potential in preclinical cancer models.

Research Area

Cell Biology, Metabolism Research, Signal Transduction

Images & Validation

Key Properties

CAS Number227619-96-7
MW420.91
Purity99.82%
FormulaC25H22ClFN2O
SMILESC(C(NCC1=CC=CC=C1)=O)C=2C=3C(/C(=C\C=4C=CN=CC4)/C2C)=CC=C(F)C3.Cl
TargetApoptosis,PDE,Microtubule Associated
SolubilityDMSO:16.67 mg/mL (39.6 mM)

Bioactivity

In Vivo
CP-461 inhibits the growth of a broad range of human tumor cell lines in vitro at micromolar concentrations and selectively induces apoptosis in cancer cell lines but not normal cells. Preclinical studies revealed good oral bioavailability and no toxicity in dogs and rats at single doses of up to 500 mg/kg. In a Phase I trial, 21 patients with a range of solid tumors and good performance status received CP-461 p.o. twice daily for 28 consecutive days. Cycles were repeated without a treatment-free interval. CP-461 doses ranged from 100 to 800 mg/day. Therapy was well tolerated overall, and a maximum tolerated dose was not reached. Grade 3 asymptomatic aspartate aminotransferase/alanine aminotransferase elevation in 1 patient treated at 800 mg/day was the only dose-limiting toxicity. No hematologic toxicity was noted. Peak plasma concentrations occurred between 1 and 2 h after dosing, and doses above 200 mg/day exceeded the known in vitro EC(50) (1-2 micro M) for apoptosis in cancer cells. No drug was detectable after 24 h of administration, and the terminal half-life was 6.7 h. The area under the plasma concentration-time curve was dose-proportional from 200 to 800 mg/day. Four patients exhibited disease stability after two cycles of treatment. CP-461 is minimally toxic at doses up to 800 mg/day when administered p.o. on a twice-daily schedule.

Storage & Handling

StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Apoptosis, CP 461, CP461, CP-461, PDE2, UNII-68OJX9I7DT, OSI 461, OSI461, OSI-461
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

CP 461 (orb1697727)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

1 mg
¥ 2,080.00
5 mg
¥ 3,900.00
10 mg
¥ 5,590.00
25 mg
¥ 8,320.00
50 mg
¥ 11,180.00
100 mg
¥ 14,690.00
200 mg
¥ 19,760.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry